New analysis says eradicating polio a better option than extended control of the diseaseApril 12, 2007Boston, MA — Concerns about the high perceived costs of eradicating the relatively low number of polio cases worldwide have led to recent suggestions that it is time to shift from a goal of eradication to control—abandoning eradication and allowing wild poliovirus to continue to circulate, which proponents of control believe can sustain the low number of cases. In a new study, researchers from the Harvard School of Public Health (HSPH) analyzed the costs and health outcomes of control and eradication options. They found that the relatively high short-term costs of global polio eradication will ultimately be much lower than the long-term financial and human health costs required to control polio forever. The study appears online April 11 and in the April 21, 2007 print issue of The Lancet. Poliomyelitis, which mainly affects children, is a highly infectious viral disease that can cause inflammation of motor neurons of the brainstem and spinal cord and lead to paralysis. Although successfully eliminated in the U.S. and most of the world through the use of poliovirus vaccines, endemic wild polioviruses still continue to circulate in some countries (notably in parts of India, Nigeria, Pakistan and Afghanistan). Since 1988, the Global Polio Eradication Initiative has reduced the global incidence of poliomyelitis by 99%, at a cost of more than $4 billion. Kimberly Thompson, Associate Professor of Risk Analysis and Decision Science at HSPH, and Radboud Duintjer Tebbens, a research associate at HSPH, used a mathematical model to demonstrate the importance of maintaining and increasing the immunization intensity in currently endemic areas. Immunization intensity is an indication of the level of vaccination effort aimed at increasing population immunity. The authors suggest that even a relatively small decrease in intensity of immunization could lead to relatively large outbreaks. They emphasized that the world cannot let up in its vaccination efforts for polio, at least until eradication has been achieved.
Comparing the numbers of expected cases and costs for 20 years into the future for a range of eradication and control options, the authors found that eradication is the best solution. For example, a control policy that relied only on routine immunization could lead to approximately 200,000 expected paralytic polio cases every year in low-income countries. "As long as it is technically achievable, eradication offers both lower cumulative costs and cases than control in the long-term, even with the costs of achieving eradication exceeding several billion dollars more," said Thompson. The authors note in the study that debate about eradication versus control should include careful consideration of the trade-offs of the options. "Control means high costs and low cases forever or low costs and high cases forever, but not low costs and low cases forever, which is only an option if we continue to pay high costs in the short-term until we eradicate," said Thompson. Although the price tag of potentially additional billions of dollars to eradicate polio may sound high, the study reports that paying now is the best way to keep the overall costs as low as possible. "A wavering commitment to eradication is not a good option," said Duintjer Tebbens. Harvard School of Public Health | |||||||||||||||||||||
|
Related Polio News Articles Parents follow pediatrician advice on administering MMR vaccinations News stories about an allegedly harmful link between the mumps, measles and rubella vaccine and the onset of autism had little effect on whether U.S. parents immunized their children, according to a review of immunization records and news stories. Parents' decisions were more likely influenced by recommendations from their child's pediatrician, the researchers said. Combination vaccine protects monkeys from ebola and Marburg viruses An experimental, combination vaccine against Ebola and Marburg viruses using virus-like particles (VLPs) provides complete protection against infection in monkeys. Cleaner water through nanotechnology Tiny particles of pure silica coated with an active material could be used to remove toxic chemicals, bacteria, viruses, and other hazardous materials from water much more effectively and at lower cost than conventional water purification methods, according to researchers writing in the current issue of the International Journal of Nanotechnology. Cell death suppression increases efficacy of M2 vaccines Significant public attention has recently been focused on the development of new anti-influenza (flu) vaccines that provide protection against a broad spectrum of viral strains. One proposed strategy is to utilize conserved viral protein, M2. Clinical trials of M2-containing influenza vaccines were recently initiated by US and European companies. Case Western Reserve University School of Medicine researchers have evidence a vaccine against malaria will reduce infection and disease rates Today, researchers at the Case Western Reserve University School of Medicine's Center for Global Health & Diseases published data potentially having a strong effect on the three billion people exposed to malaria every year. The release of new data from the HVTN 502 HIV vaccine study The new analyses revealed today from the STEP HIV vaccine clinical trial are both disappointing and puzzling. At this time, the data offer no clear explanations as to why the vaccine showed no measurable efficacy or why among individuals with background immunity to the adenovirus vector, there were more HIV infections in the vaccinees as compared to those in the placebo group. IAVI statement on new analysis of STEP large-scale AIDS vaccine trial The International AIDS Vaccine Initiative (IAVI) issued the following statement from its President and CEO, Dr. Seth Berkley, following the release of the first analysis of the entire study population from a late-stage AIDS vaccine trial, known as the STEP study. Universal flu vaccine being tested on humans A universal influenza vaccine that has been pioneered by researchers from VIB and Ghent University is being tested for the first time on humans by the British-American biotech company Acambis. Tomorrow's green nanofactories Viruses are notorious villains. They cause serious human diseases like AIDS, polio, and influenza, and can lead to system crashes and data loss in computers. Poverty and environment billions could be wasted Out-of-date policies are undermining unprecedented opportunities for recent aid commitments to improve the environment and combat poverty, according to scientists at a new global research centre launched today. More Polio News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||